Lantern Pharma Inc. (LTRN)
NasdaqCM · Price as of · Nasdaq Real Time Price
- Profitability6/20
Losing money but improving: $-18.7M over the last four reported quarters versus $-20.6M the year before.
- Insider buying vs selling20/20
Insiders are net buyers: 4 open-market buys worth $200,001 vs 0 sells worth $0 across the last 2 Form 4 filings.
- Dilution and offerings1/15
Share count up 18.4% in a year and 3 offering-related filings. Heavy dilution. One nuance: offerings raise cash that can fund real growth. The score docks the certain near-term dilution; if the spending pays off, it shows up later in the profitability component.
- Analysts2
- Implied upside+745.4%
- Target range$10.00 to $25.00
- EPS expected-$0.38
- A year ago-$0.39
LTRN closed at $2.07 on Aug 28, down 21.9% since Jul 30. Chart read: price below both the 50-day and 200-day moving averages; the 50-day is above the 200-day (uptrend structure); trading at 27% of the 52-week range ($1.12 to $4.62).
Insider buying and selling at Lantern Pharma Inc. (LTRN)
The most recent Form 4 on record for Lantern Pharma Inc. (LTRN) is May 12, 2026, when Lee Troy Schalop, Director, bought $100,001 of stock. An open-market purchase is money the filer chose to put in.
| Insider | Action | Value | Date | Type |
|---|---|---|---|---|
| Lee Troy Schalop · Director | Buy | $100,001 | May 12, 2026 | Own call |
| D Jeffrey Keyser · Director | Buy | $100,001 | May 12, 2026 | Own call |
SEC filings
| Form | Filed | Description |
|---|---|---|
| 8-K | August 14, 2026 | 8-K |
| 10-Q | August 14, 2026 | 10-Q |
| SCHEDULE 13G | August 4, 2026 | View on EDGAR |
| 8-K | August 3, 2026 | 8-K |
| SCHEDULE 13G/A | July 23, 2026 | View on EDGAR |
| EFFECT | June 18, 2026 | ,, |
| S-1 | June 12, 2026 | S-1 |
| 8-K | June 2, 2026 | 8-K |
Frequently asked questions
When does LTRN report earnings?
Lantern Pharma Inc. (LTRN) is scheduled to report quarterly results on November 11, 2026, before the open. The 1-analyst consensus is -$0.38 per share for the quarter ending September 30, 2026, against -$0.39 a year earlier. It has beaten the consensus EPS estimate in all four of the last four quarters.
What do analysts expect for LTRN?
2 analysts cover Lantern Pharma Inc. (LTRN). The consensus rating is Strong buy. The average price target is $17.50, in a range of $10.00 to $25.00.
Are insiders buying or selling LTRN?
We track Form 4 filings for Lantern Pharma Inc. (LTRN). The activity listed on this page shows 2 open-market purchases. Each row is labelled Routine when the filer declared a pre-arranged 10b5-1 plan, Tax withholding when shares were sold automatically to cover the tax on a vest, or Own call when neither applies.
Where can I see LTRN SEC filings?
Recent filings are listed on this page, newest first. The latest is an 8-K filed August 14, 2026.